Marion Schroeder

Lund, M, Sweden

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 10 publications

Visual Acuity and Intraretinal Fluid as Predictive Factors for Legal Blindness and Macular Atrophy in Neovascular AMD Eyes Treated with Anti-VEGF: A Swedish Real-World Study.

Visual Acuity and Intraretinal Fluid as Predictive Factors for Legal Blindness and Macular Atrophy in Neovascular AMD Eyes Treated with Anti-VEGF: A Swedish Real-World Study.

Journal: Clinical ophthalmology (Auckland, N.Z.)

Published: December 02, 2025

The impact of COVID-19 on aflibercept treatment of neovascular AMD in Sweden - data from the Swedish Macula Register.

The impact of COVID-19 on aflibercept treatment of neovascular AMD in Sweden - data from the Swedish Macula Register.

Journal: BMC ophthalmology

Published: September 11, 2023

A novel phenotype associated with the R162W variant in the KCNJ13 gene.

A novel phenotype associated with the R162W variant in the KCNJ13 gene.

Journal: Ophthalmic genetics

Published: April 28, 2022

What about the fellow eye in treatment of neovascular age-related macular degeneration? Analysis of data from the Swedish macula register.

What about the fellow eye in treatment of neovascular age-related macular degeneration? Analysis of data from the Swedish macula register.

Journal: Acta ophthalmologica

Published: June 14, 2021

Exploration of real-world outcomes and treatment patterns in patients treated with anti-vascular endothelial growth factors for neovascular age-related macular degeneration in Sweden.

Exploration of real-world outcomes and treatment patterns in patients treated with anti-vascular endothelial growth factors for neovascular age-related macular degeneration in Sweden.

Journal: Acta ophthalmologica

Published: January 19, 2021

Electrophysiological evaluation and 18-month follow-up of two regimens with aflibercept for neovascular age-related macular degeneration.

Electrophysiological evaluation and 18-month follow-up of two regimens with aflibercept for neovascular age-related macular degeneration.

Journal: Documenta ophthalmologica. Advances in ophthalmology

Published: October 27, 2020

Twelve per cent of 6142 eyes treated for neovascular age-related macular degeneration (nAMD) presented with low visual outcome within 2 years. Analysis from the Swedish Macula Registry (SMR).

Twelve per cent of 6142 eyes treated for neovascular age-related macular degeneration (nAMD) presented with low visual outcome within 2 years. Analysis from the Swedish Macula Registry (SMR).

Journal: Acta ophthalmologica

Published: February 25, 2019

Full-field ERG as a predictor of the natural course of ABCA4-associated retinal degenerations.

Full-field ERG as a predictor of the natural course of ABCA4-associated retinal degenerations.

Journal: Molecular vision

Published: August 11, 2017

No improvement in injection frequency or in visual outcome over time in two cohorts of patients from the same Swedish county treated for wet age-related macular degeneration.

No improvement in injection frequency or in visual outcome over time in two cohorts of patients from the same Swedish county treated for wet age-related macular degeneration.

Journal: Clinical ophthalmology (Auckland, N.Z.)

Published: June 28, 2017

Peripheral retinal function assessed with 30-Hz flicker seems to improve after treatment with Lucentis in patients with diabetic macular oedema.

Peripheral retinal function assessed with 30-Hz flicker seems to improve after treatment with Lucentis in patients with diabetic macular oedema.

Journal: Documenta ophthalmologica. Advances in ophthalmology

Published: December 19, 2014

Showing 1-10 of 10

Last Updated: 09/26/2026